Thursday, June 26, 2008

Thank You, Colorado. It Has Been Magical…

Dear Cherished CLSDF Readers,

It is with a crashing wave of mixed emotions that I report this to be my final post as author of CLSDF. It is nearly three years to the day and over 500 posts since CLSDF launched, first as an experiment in learning about the blogosphere and new technologies yet rapidly evolved into an information node for members of the Colorado life science ecosystem and beyond.

When I began tinkering with this blog I never dreamt it would develop into the resource that you have indicated to me it is through countless emails, calls, meetings, texts, instant messages, tweets and blog comments. An infinite loop emerged, for the more acknowledgement and appreciation that was expressed by the reading audience the more motivated I became to deliver meaningful content in a consistent and reliable manner.

Perhaps the most selfish element extracted from authoring CLSDF has been the opportunity to connect with an incredibly vast array of special individuals, in Colorado and beyond. Relationships were forged that undoubtedly never would have without the blog. It truly has been an honor and a privilege and just plain fun for generating content never once felt like work to me, CLSDF is a chimera of my passions for the life sciences and the people who dedicate their lives to the advancement of global healthcare.

There have been so many people to whom I am forever indebted to and appreciative of. Too many to name here, but if you take a look at the acknowledgments page in CLSDF 2007: What’s In A Year (HERE) you will see what I am talking about. One person though whom I am moved to highlight is Robin, my betrothed, who showers me with extraordinary levels of support and encouragement; I truly feel like the luckiest man in the world to have her in my life.

As I began to share the news of the unwinding of CLSDF with community members it became unambiguously clear to me that the blog has grown to be bigger than me, and though I will no longer be banging out posts on my keyboard it is imperative that this resource continue to be available to our ecosystem. With that in mind I am actively pursuing the identification of the individual (or individuals) to whom the baton may be confidently passed. So if you enjoy looking under the hoods of life science companies, interfacing with amazing people and adding a bit of a personal flair to the news please email me (arubenstein@rnaventures.com). It may be next week or next month or next year (hopefully it does not take that long) but CLSDF version 2.0 will be back and better than ever. Perhaps you know someone who would be perfect to take the reigns, please send them my way.

Finally, I can hardly contain my level of excitement as I prepare today to embark upon my next journey. It is an extraordinary opportunity and am truly blessed to be able to participate. As a youngster I enjoyed the regular occasions to be deposited in front of the tele by Dad to enjoy with him the long running CBS series Sunday Morning, little did I know the impact that then host Charles Kuralt would have in contributing to my affinity for prose, poetry and journalism. And so I find it ironically fitting that I part levering some of his echoing words...

"Time for us to part, you and I. Saying goodbye to the readers of Colorado Life Science Deal Flow is like saying goodbye to old friends. That’s the way I feel. Thank you for making me feel that way. There is a rhyme by Clarence Day which says what I want to say: 'Farewell, my friends-farewell, and hail/I'm off to seek the Holy Grail/I cannot tell you why. Remember, please, when I am gone/'twas aspiration led me on./Tiddly, widdly, toodle-oo/All I want is to stay with you.' But...here I go. Goodbye."

GlobeImmune is Fierce!


Congratulations to GlobeImmune for being named to Fierce Biotech’s 2008 Fierce 15 List (click HERE for a link to see the other 15 companies)! What makes it Fierce: GlobeImmune's third round of financing last fall was its biggest, $41.2M, bringing its total venture haul to north of $88M. Wexford capital led the round and Celgene, Boston Life Science Venture, Morgenthaler Ventures and Biogen Idec all participated. The money takes the company to a crucial inflection point: Phase II data that determines if the company's platform technology can deliver the kind of T-cell response it is looking for. GlobeImmune has three mid-stage studies underway to determine if its genetically modified recombinant yeast can induce T-cells to attack pancreatic cancer and hepatitis C.

GlobeImmune has been developing Tarmogens (Targeted Molecular Immunogens) based on scientific research in-licensed from the University of Colorado. And its development programs in divergent areas like hep C and cancer underscores just how broad a range the company could have. One successful program could lead to several more. Enrollment for the hepatitis C Phase II was wrapped in May. The study for pancreatic cancer is underway and a Phase IIa in non-small cell lung cancer--enrolling patients with a ras mutation--was launched in March. A successful mid-stage trial sets the stage for broadening the company's research activities, is likely to excite new partnership interest and also moves the company one step closer to evaluating its worth in a potential IPO.

*NOTE* Feel the power of the Colorado BioScience Association (HERE)!
*NOTE* Take a look at the new Boulder Biotech Company Tree (HERE)!
*NOTE* Read the new eBook CLSDF 2007 - What's In A Year? (HERE)!

If you enjoyed this post get free email or RSS updates (here).

Colorado: An Emerging Cluster!


On the heels of last weeks publications from Families USA’s Global Health Initiative report, ranking Colorado No. 4 among states that generated the most economic activity per dollar of funding from the NIH, and the 2008 Milken Institute State Technology and Science Index ranking Colorado 3rd, trailing only Massachusetts and Maryland, based on technology and science assets and the ability to lever said assets for economic growth, comes now from Genome Technology a report on Best Biotech Places and Emerging Clusters (HERE). In addition to highlighting Colorado as a premiere emerging cluster the other US-based emerging clusters included Texas, Tennessee, Kansas, Alabama and New York. Clearly Colorado has made tremendous strides of late and remains affixed on a very promising trajectory!

Tuesday, June 24, 2008

BioBeers Tonight: Be There or Beware


But before you attend BioBeers be certain to attend the Colorado Bioscience Association BioBoulder Networking Reception 5:30 – 7:00 at Rembrandt Yard. More info (HERE). Then just when you think it is time to head home for dinner, enjoy a summer evening with the family and walk the dog beware, because it is actually time for BioBeers 7:00 – ?, just a few blocks away at the Foundry Roof-top Deck. More info (HERE). It is an all night BioBoulder networking extravaganza.

There is also a little wrinkle thrown in for tonight. We are holding an informal poll to help determine where to feature the next BioBeers, how can you cast your vote? Simple…if you are a Denverite headed north for the night check in with me and if you are a Ft. Collinsite headed south for the night check in with me. If more friends from the north arrive at BioBeers then it is Ft. Collins for July, if more friends from the south arrive at BioBeers then it is Denver for July, and if it is a tie then it is back to Boulder for July.

*NOTE* Feel the power of the Colorado BioScience Association (HERE)!
*NOTE* Take a look at the new Boulder Biotech Company Tree (HERE)!
*NOTE* Read the new eBook CLSDF 2007 - What's In A Year? (HERE)!

If you enjoyed this post get free email or RSS updates (here).

Replidyne: Fare The Well Faropenem…


An unfortunate day indeed as Replidyne (NASDAQ: RDYN) has terminated their licensing deal with Asubio Pharma for its lead drug candidate Faropenem and subsequently is expecting a charge of approximately $4.1M. Recall, Replidyne discontinued enrollment in a late-stage study testing its faropenem medoxomil oral antibiotic as a treatment for patients with acute chronic bronchitis due to an inability to secure a partner for the clinical program.

Concomitant to the terminated license agreement is termination of the supply agreement with Nippon Soda Co. Engineering costs and delayed compensation fees comprise a portion of the expected $4.1M charges.

The decision to end Faropenem is disappointing in a variety of dimensions and to a certain extent somewhat surprising that a partner could not be identified given how mature the asset is. The termination decision was executed in order to preserve cash and focus attention on the previously discussed strategic initiatives of the C. difficile infection program and novel anti-infective programs based on DNA replication inhibition technology. As of 31 May Replidyne had cash and short term investments totaling $71.5M.

*NOTE* Feel the power of the Colorado BioScience Association (HERE)!
*NOTE* Take a look at the new Boulder Biotech Company Tree (HERE)!
*NOTE* Read the new eBook CLSDF 2007 - What's In A Year? (HERE)!

If you enjoyed this post get free email or RSS updates (here).

Monday, June 23, 2008

Back in the Saddle...


I’m playing catch-up today after attending the week long BIO2008 conference last week. It was an incredible experience (again) on a variety of levels and so too was the opportunity to again be an invited conference guest blogger. Despite the technological hurdles faced I was able to get to a few postings, here is a review and links:

Wednesday, June 18, 2008

Something Funny on the Way to a Breakout Session


Sitting in amazement of the logistical tango displayed by the BIO organizers on just exactly how does one feed 20,000+ attendees in a sophisticated and elegant manner, needless to say the Keynote Luncheon #1 was executed to perfection. Whilst hacking away at a blog post my PC endured the dreaded blue screen of death. What’s worse is that the drive has spun out into an infinite loop of blue-screen-reboot-repeat. Not so funny…luckily I have access to the beautifully appointed BIO media/press room. Thank you BIO! So the posts may not come as fast and furiously as was anticipated. Oh well, best laid plans of mice and men…

A reader of the AR Post’s will undoubtedly pick up a common denominator, that being Colorado, for obvious reasons, as I write the Colorado Life Science Deal Flow blog. I could barely contain my excitement while in the first Breakout Session Do You Have a Clue What Big Pharma is Looking For?, not one, not two but three Colorado companies/assets were mentioned in the first few breaths of the panelists, they being:

Pharmion
Array Biopharma
Macugen

Whilst departing lunch, head hung low as a result of my technological woes with one seemingly former laptop, I could not make it a ten-feet without running into a few more Colorado biocompatriots including Dan Stinchcomb, President & CEO of InViragen and Rick Silva, Director of the University of Colorado Technology Transfer Office .

Back to the Breakout Sessions Finance Track for Ice Cold to Red Hot: Turn-Around in the Diagnostics Value Proposition. Hope to see you at the party tonight on the USS Midway.

Tuesday, June 17, 2008

BIO-EVE and BIO Day 1 – Anticipated Fashion Faux Pas


Having evolved into now a BIO veteran has yielded some very important lessons for a successful conference, one in particular that has resonated is - wear comfortable shoes. There is a lot of walking to be done over the four days and therefore I have elected to choose function over fashion and swap out the Ferragamo and Prada loafers for my running shoes with my back-saving orthotic inserts. So please refrain from summoning the fashion police when you see the zapatos paired with the Gucci and Armani on top…I and my pain free back thank you.

If you happen upon my friend Steve Albainy-Jenei from Patent Baristas early in the day in the exhibit hall be certain to ask him for a iBarista iPod, no easier iPod giveaway that I am aware of, more info (here).

Tomorrow is certain to be an action packed day however, I am already looking forward to the evening activity – the Welcome Reception Party – at the USS Midway Aircraft Carrier. Please stop me and at the party and say hi. And now a few sights from BIO-EVE:





myBIO2008 Mobile = Value-add


Technology has permeated all aspects of BIO2008, one of the coolest additions is the myBIO mobile addition, this offering may come in handy (pun intended) for all of you Blackberry and iPhone addicts. The value proposition is multifold, in the palm of your hand one may simply:

  • Locate exhibitors and booth numbers
  • Locate sessions (by date/time/place)
  • Build a ‘visit plan’
  • Even book reservations for hotels, restaurants or call a cab
I’ve installed myBIO on my Blackberry Curve. It took a little tinkering to get up and running and perhaps these hints my make your installation efforts seamless.
  1. Before you start have your badge number handy (you can find this on your registration confirm email or if you have it already the number is hanging around your neck)
  2. If you have a US cell number there is no country code necessary
  3. Enter your mobile number (HERE) to get going (if the link is broken copy/paste http://mybio.boopsie.com/v2/txt/
  4. A text will be sent to your device, click on the link
  5. Be certain to then select the corresponding download option that correlates with your devices operating system. This is where problems may occur if you select the wrong version to install. Not to fret however, if the wrong version is installed simply uninstall, find the correct version and install
  6. Once installed be certain to reboot your device
Finally, the application icon on your mobile desktop is called “Boopsie”, click on that and you are off to the races. Enjoy. If you are having problems shoot me an email at arubenstein@rnaventures.com.

Friday, June 13, 2008

Follow Me on the BIO2008 Blog!


And the new BIO2008 blog, BioOnTheRoad, is off to the races (http://BioOnTheRoad.org). I will be blogging there for the next week covering the BIO2008 conference live from San Diego. There will also be a blog feed to the conference homepage at http://BIO2008.org. Where appropriate I will cross blog certain posts. Right now you can subscribe via RSS, I'll see if we can get and email subscription option going too.

Thursday, June 12, 2008

CLSDF: Subscriber Growth Update


I am excited to announce CLSDF has added another 100 subscribers; the blog is now north of 500, passing the 400 mark only 3 months ago in March. My infinite appreciation to all of you for subscribing, your feedback (both positive and negative) is treasured and motivating.

If you find CLSDF to be of continuing value than I ask that you inform your friends and colleagues about the resource and let them know how easy it is to become a subscriber. Simply send them a link to http://CLSDF.com. Thank you!

A few other quick reminders:

  1. If you are interested in forwarding a particular post to someone simply click on the ‘Email This’ tab at the bottom of each post
  2. At the bottom of each post are also options to add a particular post to your DEL.ICIO.US, Facebook, Digg or StubleUpon accounts
  3. Looking to do some networking? Be certain to attend the next BioBeers, more info (HERE). Next event 24 June 7:00pm to immediately follow the CBSA BioBoulder 5:30 event.
  4. If you are looking for the CLSDF, 2007 – What’s In A Year? ebook you can read it (HERE)
Finally, thank you all for your continued support! The Colorado life science ecosystem is positioned at a unique time and place, filled with inspiring entrepreneurs and skilled and passionate people who help effectively move discoveries along the commercialization pathway; I am both honored and humbled to be along for the ride as Colorado ascends towards greatness.

Ceragenix Pilot Study Results for EpiCeram®


Ceragenix Pharmaceuticals (OTCBB: CGXP) announced positive results from its investigator-blinded pilot study comparing the safety and efficacy of EpiCeram® Skin Barrier Emulsion to that of Elidel® cream from Novartis (NYSE: NVS), a standard non-steroidal therapy in the treatment of mild-to-moderate pediatric atopic dermatitis (AD). Both EpiCeram® and Elidel® cream produced significant improvement in patients’ conditions after four weeks of treatment. There were no statistically significant differences between the groups treated with EpiCeram® compared to those treated with Elidel®.

Improvement in patient AD was a secondary endpoint of the study. Both treatments demonstrated a statistically significant reduction. Itching, a hallmark symptom of AD, was another secondary endpoint of the study. Both EpiCeram® and Elidel® cream produced significant relief from itching after 28 days of treatment, and there was no statistically significant difference between the two treatments in reduction of itching at this time point. The research was conducted by clinicians at the Oregon Health & Sciences University and the University of California School of Medicine, San Diego.

Atopic dermatitis is a chronic childhood skin condition that may affect patients for many years. Dermatology agents currently used to treat atopic dermatitis and other inflammatory skin disorders have limitations of use due to various safety concerns. The use of EpiCeram® does not raise any of the safety concerns associated with the use of topical steroids or topical immunosuppressants.

Tuesday, June 10, 2008

QLT Reaches $140M Agreement with Allergan


QLT, Inc. (NASDAQ: QLTI) announced that QLT USA, its wholly-owned subsidiary, has entered into an asset purchase agreement with Allergan (NYSE: AGN) to fully divest QLT’s worldwide rights to Aczone®, a prescription topical medicine approved in the United States and Canada for the treatment of acne vulgaris. Under the terms of the agreement, QLT will receive a one-time cash payment of approximately $140M, and is expected to close in 3Q08.

The Aczone® asset purchase agreement is the second agreement entered into by the Company to divest non-core assets since it announced its strategic restructuring earlier this year. Other assets offered for sale from QLT USA include Eligard® and the Atrigel® drug delivery system.

*NOTE* Feel the power of the Colorado BioScience Association (HERE)!
*NOTE* Take a look at the new Boulder Biotech Company Tree (HERE)!
*NOTE* Read the new eBook CLSDF 2007 - What's In A Year? (HERE)!

If you enjoyed this post get free email or RSS updates (here).

SomaLogic + Otsuka = Early Detection + Diagnosis


Otsuka Pharmaceutical entered into a collaboration agreement to use SomaLogic’s proprietary aptamer technology to discover and develop novel diagnostic products and to design research tools that will enhance Otsuka’s discovery and development efforts.

SomaLogic will receive research funding and will be entitled to receive a royalty on any marketed products developed as a result of the collaboration. Otsuka also received an option to acquire distribution rights in Asia for certain SomaLogic clinical diagnostics products. In addition, SomaLogic received an equity investment from Otsuka. Other financial terms were not disclosed. Finally, note that SomaLogic is hiring! Take a look (HERE).

*NOTE* Feel the power of the Colorado BioScience Association (HERE)!
*NOTE* Take a look at the new Boulder Biotech Company Tree (HERE)!
*NOTE* Read the new eBook CLSDF 2007 - What's In A Year? (HERE)!

If you enjoyed this post get free email or RSS updates (here).

Thom Cech on 60 Minutes


Colorado life scientist’s and life science companies have recently been appearing left and right in the national spotlight, first in Popular Science then in Newsweek and now…Did you happen to catch 60 Minutes this past Sunday night? If not, the segment on Howard Hughes and how the Howard Hughes Medical Institute came to fruition featured one Colorado-bound Thom Cech. If you have a few moments you can watch the video below, in addition is a video interview of Thom that I find very interesting and hope you will too [if you are reading this via email or RSS aggregator you will have to click over to http://CLSDF.com to view the videos].





*NOTE* Feel the power of the Colorado BioScience Association (HERE)!
*NOTE* Take a look at the new Boulder Biotech Company Tree (HERE)!
*NOTE* Read the new eBook CLSDF 2007 - What's In A Year? (HERE)!

If you enjoyed this post get free email or RSS updates (here).

Sunday, June 08, 2008

Allos: Positive Phase I Interim Data for PDX


Allos Therapeutics (NASDAQ: ALTH) announced positive interim data from their Phase I dose optimization study of PDX (pralatrexate) with vitamin B12 and folic acid supplementation in patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL). The data demonstrated activity in a range of doses, and will continue with the objective of determining the optimal dose and schedule for patients with CTCL.

Data were presented on 17 patients, including 14 evaluable patients who completed at least one cycle of treatment with PDX at doses ranging from 15-30 mg/m2 as part of a weekly schedule for two or three weeks followed by one week of rest. Patients received a median of three prior systemic therapies. Investigator-assessed responses were observed in 7 of 14 evaluable patients, including two complete responses and five partial responses. Responses were observed in all four treatment cohorts. The most common adverse event was mucositis.

*NOTE* Feel the power of the Colorado BioScience Association (HERE)!
*NOTE* Take a look at the new Boulder Biotech Company Tree (HERE)!
*NOTE* Read the new eBook CLSDF 2007 - What's In A Year? (HERE)!

If you enjoyed this post get free email or RSS updates (here).

Thursday, June 05, 2008

GambroBCT is Now CaridianBCT


Perhaps 2008 will commemorate a year of transition for the Colorado life science ecosystem marked now by a third company to announce a name change.

CaridianBCT origins date back to 1964 when founders Bob Collins and Ran Bellows established COBE Laboratories to meet emerging needs for custom heart-lung tubing packs. COBE evolved into a market leader in the blood component technology and medical specialty products industry. In 1990, Sweeden-based Gambro AB acquired COBE to form GambroBCT. And now a new name change, from GambroBCT to CaridianBCT, has been architected to emphasize business unit independence from the parent company and concurrently enhance its global branding efforts.

It’s exciting to see CaridianBCT continue its storied history and new chapter as a leading global provider of technology, products and services in automated blood collections, therapeutic systems, whole blood processes and pathogen reduction technologies - serving blood banks, hospitals and clinical and biotech research facilities. Headquartered in Lakewood, CO., the company is Colorado’s largest medical device manufacturer with global revenues nearing $500M with operations in 32 countries and 1,800 of their 2,300 employees call the Rockies home.

*NOTE* Feel the power of the Colorado BioScience Association (HERE)!
*NOTE* Take a look at the new Boulder Biotech Company Tree (HERE)!
*NOTE* Read the new eBook CLSDF 2007 - What's In A Year? (HERE)!

If you enjoyed this post get free email or RSS updates (here).

Wednesday, June 04, 2008

$76.1M From NIH to Fund CCTSI


Congratulations to the University of Colorado Denver for receiving a $76.1M five-year grant from the NIH designed to accelerate scientific discovery towards commercialized products, improve patient health and fulfill the critical need to train the next generation of clinical and translational researchers. These goals and more are to be achieved within the virtual walls of the newly established Colorado Clinical and Translational Sciences Institute (CCTSI).

The Institute’s five areas of focus are: converting laboratory research to clinical use, applying clinical lessons in communities, discovering new methods and applying technologies to measure and analyze data, training future researchers and advancing child and maternal research. CCTSI will achieve its aims via the architecting of an unprecedented regional partnership among the UC Denver Schools of Medicine, Dentistry, Pharmacy, Public Health, Graduate School and College of Nursing, as well as CU-Boulder, University of Colorado Hospital, The Children's Hospital, Denver Health, National Jewish Medical and Research Center, the Denver Veterans’ Affairs Medical Center and Kaiser Permanente of Colorado.

The NIH created the Clinical and Translational Science Award to stimulate collaboration between leading academic health centers, health care organizations, the private sector and the communities they serve. The result is a historically large public investment in health care research and training that promises to pay similarly large and historic dividends. The CCTSI will conduct state-of-the art clinical research, under careful oversight to assure participant safety.

The University of Colorado Denver join the following institutions who have received similar funding from the National Institutes of Health’s Clinical and Translational Science Award consortium:

  • Albert Einstein College of Medicine of Yeshiva University
  • Boston University
  • Harvard University
  • Indiana University School of Medicine
  • Northwestern University
  • The Ohio State University
  • The Scripps Research Institute
  • Stanford University
  • Tufts University
  • The University of Alabama at Birmingham
  • The University of North Carolina at Chapel Hill
  • The University of Texas Health Science Center at San Antonio
  • The University of Utah
For a bit more depth be certain to observe the powerpoint below presented by Ronald Sokol, MD Director of CCTSI (If reading this in an email or RSS feed pop over to http://CLSDF.com to observe the slide deck).

SlideShare | View |

*NOTE* Feel the power of the Colorado BioScience Association (HERE)!
*NOTE* Take a look at the new Boulder Biotech Company Tree (HERE)!
*NOTE* Read the new eBook CLSDF 2007 - What's In A Year? (HERE)!

If you enjoyed this post get free email or RSS updates (here).

Tuesday, June 03, 2008

Pages of Newsweek Featuring Ventria Bioscience


On the heels of Tensegrity Prosthetics prominent feature in Popular Science (HERE) comes a recent Newsweek article (HERE) presenting a high level description of the green gene revolution or the marriage of biotechnology and agriculture. When referring to the art of leveraging agricultural products as therapeutics manufacturing plants (no pun intended…well maybe) Ventria Bioscience (Ft. Collins) was emphasized for some of their recent work.

Ventria has developed their proprietary ExpressTec technology platform – a protein/peptide production system – designed to create innovative human health products that incorporates self-pollinating crops (such as rice and barley) as the production host for these products, thereby bypassing many of the technological hurdles inherent in other protein production methods. Certain benefits of ExpressTec production process include: i) Economically advantaged expression capability (e.g. 10g/kg of brown rice) ii) Scalability for large volumes of recombinant proteins/peptides with minimal capital investment compared with other systems iii) Free of infectious or toxic contaminants iv) Self-pollinating crops provide a safe and closed production system and v) Efficient supply management - the protein/peptide can be stored in its lowest cost form for multiple years.

Ventria's ExpressTec platform has produced several proteins that have a variety of applications in human and animal health. Two specific products include recombinant human Lactoferrin and Lysozyme which are both found in human breast milk as well as most epithelial surface secretions including tears, nasogastric, saliva, and bronchial. Potential applications are in GI health for the management of acute diarrhea and certain bacterial, viral and fungal infections.

*NOTE* Feel the power of the Colorado BioScience Association (HERE)!
*NOTE* Take a look at the new Boulder Biotech Company Tree (HERE)!
*NOTE* Read the new eBook CLSDF 2007 - What's In A Year? (HERE)!

If you enjoyed this post get free email or RSS updates (here).

Monday, June 02, 2008

Pre-BIO Conference Colorado Networking Event


Do you plan to attend BIO in two weeks? If so be certain to attend the Colorado pre-conference networking reception on 10 June 5:00 – 6:30pm at the Governor’s Mansion Carriage House. Be certain to RSVP if you are planning to attend, contact Becky Chandler 303.892.3707 or becky.chandler@state.co.us. We can thank the Colorado Bio Science Association and the Colorado Office of Economic Development and International Trade for sponsoring this first official BIO 2008 event!

By the way, Governor Ritter plans to attend the BIO conference and here are a few of his thoughts on our eco-system.

"I am very excited to showcase Colorado's commitment to the bio- and life-sciences during the upcoming BIO 2008 event in San Diego," Colorado Gov. Bill Ritter said. "Colorado’s bioscience community is making incredible advances and we have a tremendous success story to tell. We recently established a Colorado Bioscience Grant Program to promote the industry and facilitate tech transfer. Colorado’s first Nobel Laureate, Tom Cech, just announced his return to the state. Our Anschutz Medical Campus at Fitzsimons and the research and development work being done in Boulder and Fort Collins are making Colorado a regional bioscience hub. My administration has made the biosciences one of the focal points of our overall economic-development strategy, and by elevating the stature of this crucial Industry of the future, we are competing on a national and international level.”


*NOTE* Feel the power of the Colorado BioScience Association (HERE)!
*NOTE* Take a look at the new Boulder Biotech Company Tree (HERE)!
*NOTE* Read the new eBook CLSDF 2007 - What's In A Year? (HERE)!

If you enjoyed this post get free email or RSS updates (here).